Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

Brain Research

Volumn 1007, Issue 1-2, 2004, Pages 152-159

  De Lago, Eva ^a   De Miguel, Rosario ^a   Lastres Becker, Isabel ^a,b   Ramos, José A ^a   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Anandamide; Basal ganglia; Capsazepine; Motor activity; Motor systems and sensorimotor integration; Nigrostriatal dopaminergic neuron; Vanilloid like receptor

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; POTASSIUM ION; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DATA ANALYSIS; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; HYPOKINESIA; HYPOTHESIS; IN VITRO STUDY; IN VIVO CULTURE; LOCOMOTION; MALE; MOBILIZATION; NERVE ENDING; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PUTAMEN; RAT; STEREOTYPY; TIME;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; CAPSAICIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DRUG INTERACTIONS; ELECTROCHEMISTRY; ENDOCANNABINOIDS; ION CHANNELS; MALE; MOTOR ACTIVITY; NEURONS; POLYUNSATURATED ALKAMIDES; POTASSIUM; RATS; RATS, WISTAR; RECEPTORS, DRUG; STEREOTYPED BEHAVIOR; TRPV CATION CHANNELS; TYROSINE 3-MONOOXYGENASE;

EID: 1942503254     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.02.016     Document Type: Article

References (46)

1. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernández-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Comm. 256:1999;377-380.
2. Chan P.K., Chan S.C., Yung W.H. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. NeuroReport. 9:1998;671-675.
3. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5:1998;534-551.
4. De Lago E., Fernández-Ruiz J., Ortega-Gutierrez S., Viso A., López-Rodriguez M.L., Ramos J.A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449:2002;99-103.
5. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483:2000;52-56.
6. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., Fernández-Ruiz J.J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. 420:2001;123-131.
8. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fat. Acids. 66:2002;377-391.
9. Fernández-Ruiz J.J., Berrendero F., Hernández M.L., Ramos J.A. The endogenous cannabinoid system and brain development. Trends Neurosci. 23:2000;14-20.
10. Fernández-Ruiz J.J., Lastres-Becker I., Cabranes A., González S., Ramos J.A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot. Essent. Fat. Acids. 66:2002;263-273.
11. Gerdeman G., Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85:2001;468-471.
12. González S., Romero J., de Miguel R., Lastres-Becker I., Villanúa M.A., Makriyannis A., Ramos J.A., Fernández-Ruiz J.J. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 65:1999;327-336.
13. Herkenham M., Lynn A.B., Little M.D., Melvin L.S., Johnson M.R., de Costa D.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
14. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991;264-267.
15. Hernández M.L., Berrendero F., Suarez I., García-Gil L., Cebeira M., Mackie K., Ramos J.A., Fernández-Ruiz J. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res. 857:2000;56-65.
16. Iversen L. Cannabis and the brain. Brain. 126:2003;1252-1270.
17. Khanolkar A.D., Abadji V., Lin S., Hill W.A., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
18. 1 receptors and alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse. 44:2002;23-35.
19. Lastres-Becker I., de Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernández-Ruiz J.J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 84:2003;1097-1109.
20. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S., Lastres-Becker I., González S., Fernández-Ruiz J.J., Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 44:2001;4505-4508.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
23. 9-THC reduces GABA uptake in the globus pallidus. Eur. J. Pharmacol. 308:1996;161-164.
24. Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3655-3660.
25. Miller A., Walker J.M. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur. J. Pharmacol. 304:1996;29-35.
26. Miller A., Walker J.M. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur. J. Pharmacol. 352:1998;199-205.
27. Miller A., Sañudo-Peña M.C., Walker J.M. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res. 793:1998;7-11.
28. Nagatsu T., Oka K., Kato T. Highly sensitive assay for tyrosine-hydroxylase activity by high-performance liquid chromatography. J. Chromatogr. 163:1979;247-252.
29. 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol. Biochem. Behav. 45:1993;291-298.
30. Palkovits M., Brownstein J. Maps and Guide to Microdissection of the Rat Brain. 1988;Elsevier, New York,USA.
31. 2 receptors. Pharmacol. Ther. 74:1997;129-180.
32. Romero J., García L., Cebeira M., Zadrozny D., Fernández-Ruiz J.J., Ramos J.A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci. 56:1995;2033-2040.
33. Romero J., de Miguel R., García-Palomero E., Fernández- Ruiz J.J., Ramos J.A. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res. 694:1995;223-232.
34. Romero J., García-Palomero E., Fernández-Ruiz J.J., Ramos J.A. Involvement of GABA-B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav. Pharmacol. 7:1996;299-302.
35. Romero J., de Miguel R., Ramos J.A., Fernández-Ruiz J.J. The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake. Life Sci. 62:1998;351-363.
36. Romero J., Lastres-Becker I., de Miguel R., Berrendero F., Ramos J.A., Fernández-Ruiz J.J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological and therapeutic aspects. Pharmacol. Ther. 95:2002;137-152.
37. Sañudo-Peña M.C., Walker J.M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77:1997;1635-1638.
38. Sañudo-Peña M.C., Tsou K., Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65:1999;703-713.
39. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22:2001;565-572.
40. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
41. Szabo B., Dorner L., Pfreundtner C., Norenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
42. Szabo B., Wallmichrath I., Mathonia P., Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience. 97:2000;89-97.
43. 1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
44. Wiley J.L., Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids. 121:2002;57-63.
45. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.
46. Zygmunt P.M., Chuang H., Movahed P., Julius D., Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396:2000;39-42.